The First Affiliated Hospital of Xiamen University: clinical-trial pipeline
The First Affiliated Hospital of Xiamen University is the sponsor of 118 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 70 are not yet finished and 3 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 59 |
| Phase 2 | 36 |
| Phase 1 | 7 |
| Phase 1/2 | 6 |
| Phase 4 | 4 |
| Early phase 1 | 3 |
| Phase 3 | 2 |
| Phase 2/3 | 1 |
Trials by status
| Status | Trials |
|---|---|
| Recruiting | 59 |
| Unknown | 28 |
| Completed | 19 |
| Not yet recruiting | 8 |
| Active, not recruiting | 3 |
| Terminated | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 80 |
| Metabolic and endocrine (diabetes, obesity) | 12 |
| Gastroenterology and liver | 9 |
| Nephrology and urology | 9 |
| Cardiovascular | 5 |
| Rare and genetic diseases | 5 |
| Immunology and rheumatology | 4 |
| Haematology | 3 |
| Women's health and obstetrics | 3 |
| Musculoskeletal | 2 |
| Ophthalmology | 2 |
Countries
| Country | Trials |
|---|---|
| China | 110 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-21 | New trial posted | 68Ga-XMFH01 PET/Fluorescence Imaging in Prostate Cancer |
| 2026-10-21 | New trial posted | 68Ga-XHER2 PET/CT for HER2 Assessment |
| 2026-10-20 | New trial posted | Anxiety and Depression in Patients With Hematologic Malignancies |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT07623382 | Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye… | Early phase 1 | Recruiting | China |
| NCT06757023 | A Clinical Follow-up Study on the Efficacy of Thumbtack Needle for Postoperative Sleep and Recovery Treatment | Not applicable | Recruiting | China |
| NCT06151080 | Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL | Phase 2 | Recruiting | China |
| NCT07046689 | PET/CT for Trop2 ADC Response Evaluation Cancers | Not applicable | Recruiting | China |
| NCT06415669 | A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcin… | Phase 2 | Recruiting | China |
| NCT07046702 | 68Ga-MY6349 PET/CT in Solid Tumors | Not applicable | Recruiting | China |
| NCT06956144 | Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients | Not applicable | Recruiting | China |
| NCT06151106 | Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma | Phase 2 | Recruiting | China |
| NCT07034963 | Study on the Effective Dose and Safety of Esketamine in Hysteroscopic Surgery Under Monitored Anesthesia Care | Phase 1/2 | Active, not recruiting | China |
| NCT03799653 | A Prospective Nurse Cohort Study in Xiamen, China | Not applicable | Recruiting | China |
| NCT07165158 | The Effect of Semaglutide on Bone Health | Phase 4 | Not yet recruiting | China |
| NCT06929936 | Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metasta… | Phase 2 | Recruiting | China |
| NCT07438093 | Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibod… | Not applicable | Not yet recruiting | China |
| NCT06581640 | Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple M… | Phase 2 | Recruiting | China |
| NCT06754345 | 68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers | Not applicable | Recruiting | China |
| NCT06651853 | Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL | Phase 2 | Recruiting | China |
| NCT07085234 | Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC | Phase 2 | Recruiting | China |
| NCT03802253 | Time Restricted Eating on Impaired Glucose Regulation(TRIG Trial) | Not applicable | Active, not recruiting | China |
| NCT07018362 | Ultrasound Assessment of Fetal Growth Parameters | Not applicable | Recruiting | China |
| NCT07677774 | GPC3-Targeted PET/CT in Hepatocellular Carcinoma | Not applicable | Recruiting | China |
| NCT06375564 | Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression | Phase 1 | Recruiting | China |
| NCT06811844 | Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC | Phase 2 | Recruiting | China |
| NCT07778212 | Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk D… | Not applicable | Recruiting | China |
| NCT07677787 | DLL3-Targeted PET/CT in Small Cell Lung Cancer | Not applicable | Recruiting | China |
| NCT07189884 | Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy | Phase 1/2 | Not yet recruiting |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "The First Affiliated Hospital of Xiamen University clinical trials: 70 open, 3 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/the-first-affiliated-hospital-of-xiamen-university/, data as of 2026-10-25.